Thus, expression and splicing of RHAMM are important molecular determinants of disease severity in MM.
Introduction
Multiple myeloma (MM) is a B-cell neoplasm characterized by accumulation of clonal plasma cells (PC) in the bone marrow, secretion of a monoclonal protein (M-protein), and osteolytic lesions accompanied by bone pain and anemia 1 . MM is further characterized by chromosomal instability (CIN) and a defining VDJ rearrangement of the immunoglobulin heavy chain (IgH) gene locus, termed clonotypic 2 3 . Recurrent genetic translocations into switch recombination regions of the IgH locus occur in up to 75% of myelomas 4 5 ; one of the most common of these is t(4;14)(p16.3;q32) 4 6 . MM PC contain extensive chromosomal abnormalities, both numerical and structural 5 . The presence of specific genetic lesions are prognostic 1 4 6 .
An additional ubiquitous feature MM is the expression of the Receptor for Hyaluronan
Mediated Motility (RHAMM) 7 . RHAMM was cloned in 1992 and described as a hyaluronan binding protein 8 9 . A variant of RHAMM, that is predominantly cytoplasmic and involved in multiple signaling pathways 10 11 , is transforming and essential for ras transformation 12 .
Human RHAMM FL was cloned in 1996 as a predicted 85-95 kDa protein encoded by 18 exons 13 . RHAMM FL has been described as an actin and microtubule associated protein that localizes to the centrosome and mitotic spindle pole and is essential for mitotic stability 14, 15 . The NH 2 -terminus of RHAMM directly interacts with microtubules, via exon 4, while the COOHterminus targets the centrosome, presumably through an indirect interaction with dynein 14, 15 .
Loss of exon 4 inhibits the ability of RHAMM to interact with interphase microtubules 14 ;
disruption of the COOH-terminus, by microinjection of polyclonal antiserum, affects mitotic integrity and induces tripolar and tetrapolar spindles 15 .
While RHAMM is ubiquitously expressed in murine tissues (with elevated expression in testes, thymus and spleen) 16 , consistent detection of RHAMM expression within normal only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From human tissues appears to be limited to the testis 17 18 . Reports of RHAMM expression have identified the testis, spleen, colon, and stomach 17 , the testis, placenta and thymus 18 and the testis, placenta, lung, and pancreas 19 as RHAMM positive tissues (in decreasing orders, respectively). RHAMM expression is rare in normal peripheral blood 18 17 7 
Materials and Methods

Patients and Clinical Data
In Alberta, Canada, total RNA extracts from BM biopsies of 101 newly diagnosed MM patients were used to assess the prognostic impact of RHAMM exon 4 splicing. Sorted BM PC from an additional 22 patients were used to examine RHAMM expression and splicing at the single-cell level (n=8) and absolute RHAMM expression at the population level (n=14). Peripheral blood cellular RNA samples from 5 t(4;14)
+ MM patients were obtained at various time points in the course of disease, as described previously 6 , and were used to examine temporal changes in RHAMM expression patterns.
In Arkansas, USA, samples for microarray experiments included purified PC from a separate cohort of 210 newly diagnosed cases of MM. Isolation from mononuclear cell fraction was performed and purity was confirmed as previously described 24 . Skeletal roentgenogram surveys (n=199) and skeletal MRI (n=193) were performed on the Arkansas cases to sub-classify patients as having no focal bone lesions, at least one focal lesion, and three or more focal lesions. Arkansas patients were treated with Total Therapy II 25,26 and were followed for event-free and overall survival. Indications for treatment in patients lacking bone lesions included cytopenias, hypercalcemia, and renal dysfunction.
Total RNA isolation, cDNA synthesis, preparation of labeled cRNA, hybridization to microarrays, and analysis of GeneChip data (Arkansas patients)
Total RNA was isolated from PC using the RNeasy Mini kits (QIAGEN, Valencia, CA). Detailed protocols for cDNA synthesis, cRNA preparation, hybridization to the U95Av2 microarray (Affymetrix Inc., Santa Clara, CA) and analysis of raw data have been described 24 . All microarray data used in the analyses were derived from Affymetrix 5.0 software. The primers were designed to flank exon 4, so that two RT-PCR products of different sizes could be detected in a single reaction, representing full-length RHAMM and the splice variant lacking exon 4. A 6-FAM fluorescenated label was added to the 3' primer for detection using fragment capillary electrophoresis (FCE) (ABI3100, Applied Biosystems, Foster City, CA). RT-PCR products were visualized by ethidium bromide (EtBr) staining on 2% agarose (Invitrogen) gels or by capillary electrophoresis as described 28, 29 . Single cell RT-PCR products were precipitated prior to capillary electrophoresis, to increase sensitivity of detection. Sequencing of clonotypic VDJ was performed as described 27 .
The relative amount of exon 4 splicing in a given sample was estimated by calculating the ratio of fluorescence intensity of the RHAMM -exon4 and RHAMM FL products following RT-PCR and FCE (i.e. the RHAMM -exon4 /RHAMM FL ratio, hereafter "RHAMM ratio"). Each sample was analyzed in triplicate. Fluorescence intensity was analyzed using GeneScan ® software (Applied Biosystems).
Quantitative RT-PCR (Alberta).
only. Reactions were run on an ABI PRISM TM 7700 Sequence Detection System (Applied Biosystems). Quantitation using the Relative Standard Curve Method was performed using a 2 Log dilution range of Raji cDNA to generate a standard curve for each reaction.
Synchronization, Immunoprecipitations and quantitation (Alberta)
HeLa and Raji cells were synchronized by double thymidine block. Briefly, cells were plated at sub-confluency and incubated with, or without, 2mM thymidine for 14-16 hours.
Cells were washed, released from thymidine block and incubated in fresh media for 8 hours.
Cells were washed and the synchronized populations were incubated with 2mM thymidine for 14-16 hours. Cells were released into fresh media for 3-4 hours and synchronized populations were incubated in 300ng/ml nocodazole (Sigma) for 10-12 hours, washed with PBS and released by shake-off. Unsynchronized HeLa populations were released from plates with 1x
trypsin. Both mitotic and unsynchronized populations were then washed 3x with PBS and lysed at 5x10 6 -10 7 cells/ml in 1% CHAPs plus 10 µg/mL leupeptin, 10 µg/mL antipain and 1 only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From mM phenylmethylsulfonyl fluoride (all from Sigma). Protein quantitation utilized the Odyssey v1.1 Infrared imaging system (LI-COR) with detection of polyclonal sera using IRDye 800 conjugated anti-rabbit IgG (Rockland, Gilbertsville, PA).
Statistical Methods
Statistical analyses were performed with the software packages SPSS (SPSS, Chicago, IL).
and SAS v8 for Windows (SAS Inc., Cary, NC). Differences in proportions were compared using Fisher's Exact Test. Between-group comparisons of continuous variables were with Student's t-test, or the Wilcoxon rank sum test. Linear relationships were determined by Pearson's or Spearman's correlation coefficient. Survival curves were plotted using the Kaplan-Meier method. Comparison of survival distributions was with the log rank test.
Logistic regression was used to assess the independent associations of RHAMM and DKK1 with osteolytic lesions. Cox proportional hazards analysis was used to assess the independent prognostic significance of the RHAMM ratio. Statistical significance was set at a level of p < 0.05 using 2-sided analysis.
only.
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Results
Increased RHAMM expression levels correlate with bone lesions, but not with DKK1 expression (Arkansas patients)
The characteristics of the 210 Arkansas patients are outlined in Table 1 , for the total population as well as for the two subgroups of patients defined based on the median level of RHAMM expression. Patients expressing RHAMM at levels below the median are classified as "low" RHAMM expressers; patients above the median are classified as "high" RHAMM expressers. Among the conventional measures of disease severity listed in Table 1 , only LDH is correlated with RHAMM at a p-value of 0.05 or less.
Preliminary microarray experiments had identified RHAMM as one of the genes most highly correlated with the presence of bone lesions in myeloma 24 , prompting us to investigate further the association between RHAMM and bone lesions. The proportion of patients with 1+
MRI-detected focal bone lesions was significantly higher in the "high" than in the "low"
RHAMM expressers (Table 1 ). The association between bone lesions and RHAMM expression was also found to be significant when using the less sensitive technique of skeletal x-rays as the basis for assessment of bone disease, or when comparing only those patients with multiple bone lesions to the group lacking bone lesions (Table 1) .
A recent publication by the Arkansas group has demonstrated a significant correlation between expression of the DKK1 gene and the presence of osteolytic lesions 30 . We examined the correlation between RHAMM and DKK1 expression in the microarray experiments. Table 1 . Clinical characteristics of 210 myeloma patients from the Arkansas cohort, stratified by RHAMM expression below or above the median level for the cohort (dubbed "low" or "high" expression). RHAMM expression was determined from oligonucleotide microarray experiments on sorted MM PC. P-values refer to statistical comparisons between low and high RHAMM expressers; p-values <0.05 are labeled with an asterisk (*).
RHAMM expression correlates with poor disease-free and overall survival (Arkansas patients)
Figures 1a and 1b show overall and event-free survival for 210 Arkansas patients stratified by high versus low RHAMM expression (median cutoff) as assessed by microarray.
High RHAMM expression is significantly associated with poor outcome. The 2-year overall survival estimate for patients with high RHAMM expression is 76% and with low RHAMM is only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 13 88% (p=0.04). The 2-year event-free survival in high RHAMM expressers is 76%, versus 88% in the low RHAMM expressers (p=0.05). (Figure 2A ). Optimal PCR conditions were determined to provide reproducible RHAMM ratios from purified PC, PBMC and BM samples ( Figure 2B ).
FCE was approximately 5000x more sensitive than agarose detection, detecting PCR products resulting from amplification of attogram (10 -18 (Figure 2A ). Single and 1000 PC samples were isolated from three control patients and evaluated for RHAMM expression. Interestingly, in control samples RHAMM-expressing PC predominantly express both isoforms. A greater fraction of single PC (63% vs. 43%) lack detectable RHAMM transcripts in the control populations examined; due to low expression levels we were unable to determine RHAMM ratios within purified 1000 PC control samples. We expanded our analysis to include total RNA from unpurified BM of additional control patient (n=4) samples. Again, expression levels were too low to determine RHAMM ratios from these samples. These results strongly suggest that within populations of control PC the absolute levels of RHAMM transcripts, although detectable by extremely sensitive FCE at the single cell level, are so insignificant as to be undetectable at the bulk cell population level.
For + or CD38 + PC derived from BM aspirates, were sorted into PCR tubes containing lysis buffer at 1 cell/tube or 1000 cells/tube and stored at -80 O C. RT-PCR was performed as outlined in Methods using RHAMM-specific primers that flank exon 4. Only cDNA samples that were positive for both beta-2-microgobulin (MM and control) and clonal message (MM) are tabulated. Single cell RT-PCR products were precipitated prior to GeneScan® analysis. RHAMM specific RT-PCR amplification of 1000 cell/well samples resulted in two product peaks representing RHAMM -exon4 product (150 bp) and RHAMM FL product (200 bp). The area under each peak was calculated by GeneScan® Analysis software and exported to Microsoft® Excel to determine the ratio of RHAMM -exon4 /RHAMM FL peak intensities. UD= unable to determine. RHAMM ratios were unobtainable from 1000 PC/well (n=3 patients examined) and bulk BM(n=4 patients examined) populations from 7 control patient populations. 
RHAMM ratios measured in populations of MM PC reflects the distribution of RHAMM isoforms seen in individual clonal cells.
RHAMM ratios were determined for 1000 sorted PC from the same 8 patients who were examined at the single PC level. As expected from previous data 7, 17 
Elevated RHAMM expression, in MM patient PCs, correlates modestly with a relative increase in RHAMM -exon4 expression
We investigated whether elevated RHAMM expression was associated with preferential expression of one isoform (high or low RHAMM ratio). RNA was isolated from purified CD138 + PCs from fourteen MM patients, quantitative RT-PCR was performed as described and ratios were determined. RHAMM expression was normalized to the lowest RHAMM expresser and plotted against the corresponding RHAMM ratio for individual patients. As shown in Figure 3 , the patients clustered into three groups based upon their RHAMM ratios; three patients exhibited ratios <0.9, six patients exhibited ratios 0.9>N<1. 
RHAMM expression, but not exon 4 deletion, is upregulated during mitosis
Previous experimentation demonstrated that RHAMM expression is upregulated during mitosis in adherent (HeLa) and suspension (Raji) cell lines (Maxwell et al., submitted).
We investigated whether RHAMM ratios were also altered during mitosis. 
RHAMM ratios in the peripheral blood reflect disease burden over time
Our lab has previously published the temporal examination of Thus, for all IgH-MMSET + blood samples, at least 2% of the total PBMC population is malignant. The integrity of each cDNA sample (n=88) was confirmed with 2 -microglobulin.
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Only the t(4;14) status of the patient was known to the experimenter; the analysis was blind for all other parameters. For each patient, the RHAMM ratio was plotted against time and compared to a standard clinical measure of BM PC burden, the serum M protein level (g/L).
RHAMM ratios from samples that were positive for clonotypic transcript and for at least one t(4;14) RT-PCR reaction, as well as the immediate neighboring negative samples, are plotted and trendlines, generated with Microsoft Excel software, are given. Figure 4 illustrates results typical of the patients examined. For samples in which t(4;14) message was detected, an increase in the relative RHAMM -exon4 message was associated with increasing serum Mprotein levels. For samples lacking detectable IgH-MMSET transcript (not shown), the RHAMM ratio fluctuated from ~0.6-0.9. As shown in Figure 4 , the fluctuations of the RHAMM ratio closely approximate that of the M protein prior to transplant and following relapse. In four out of five patients examined, clinical relapse coincided with a dramatic increase in RHAMM ratios. These observations illustrate a significant association between RHAMM -exon4 mRNA expression in PBMC and tumor burden.
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High RHAMM ratios in the diagnostic bone marrow correlate with poor survival in MM
We investigated the prognostic significance of relative RHAMM -exon4 expression in diagnostic bone marrow samples. The RHAMM ratio was measured in total RNA extracts from the bone marrow of 101 MM patients from Alberta, Canada. The fact that RHAMM ratios in control BM were too low to determine RHAMM ratios indicates that the RHAMM ratio in total BM from MM patients is largely contributed by the malignant cells, justifying the use of the available total BM samples for this experiment. These patients are a subset of a previously described cohort 6 . The characteristics of the 101 Alberta patients are listed in Table 4 . These three groups exhibited significantly differing overall survival (OS) distributions ( Figure   5 ), with increasingly poorer outcomes associated with increasingly higher RHAMM ratios (p=0.003).
In a single-variable Cox model, an increasing RHAMM ratio significantly correlated with poor survival (HR=2.18, 95% CI, 1.11-4.26, p=0.024). The RHAMM ratio was an independent predictor of survival when included in a multivariable Cox regression model with albumin and ß2M as covariates (HR=3.34, 95% CI 1.14-9.79, p=0.028). Albumin and ß2M
are the factors used in the SWOG model 32 , a currently accepted standard prognostication method in MM; thus, the RHAMM ratio adds independent information to standard prognostic factors.
only. and clonotypic mRNA assays, the RHAMM ratio decreased post autologous transplant and increased at the time of relapse. While the RHAMM ratio in circulating malignant cells correlates with tumour burden, a high RHAMM ratio in the BM does not appear to be simply a measure of disease burden, since it does not correlate with the degree of marrow plasmacytosis, nor with LDH or beta-2-microglobulin levels.
Also interesting is the finding that, in eight patients, RHAMM -exon4 and RHAMM For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From expression in MM cells on this balance of bone growth and bone loss is unclear. Given the lack of correlation between RHAMM and DKK1 expression, and given the lack of any currently known biological link between the two genes, the mechanism underlying the association between RHAMM and osteolytic lesions is in all probability quite distinct from that for DKK1. The simplest explanation for the association between RHAMM levels and disease severity would be that RHAMM expression is intimately linked to myeloma proliferation; elevated RHAMM expression may be analogous to an elevated bromodeoxyuridine plasma cell labeling index (PCLI), a measure of proliferative activity that is an important prognostic factor in newly diagnosed MM 33 . However, actively cycling cell lines predominantly express RHAMM FL as indicated by their reduced RHAMM ratios.
Further, within MM patients, elevated RHAMM expression did not correlate with a high PCLI (Table 1) . A parallel hypothesis is that altered RHAMM expression may dramatically affect chromosomal segregation and chromosomal instability (CIN) within the malignant clone, analogous to the mitotic errors seen previously in our RHAMM immunoblocking experiments 15 . We have previously postulated that RHAMM mitotic function depends upon microtubule crosslinking resulting from microtubule interactions at the NH 2 -and COOH-termini 15 . Kaplan-Meier survival curves for myeloma patients with RHAMM ratios of <0.8 (red), 0.8-1.2 (green), and >1.2 (blue) in the bone marrow at diagnosis. Survival is increasingly poor with increasing RHAMM ratio (p=0.003 by the log rank test). RHAMM ratios were determined using RT-PCR and capillary fragment analysis.
